## Abstract Melanocortins, besides their central roles, have also recently been reported to regulate adipocyte metabolism. In this study, we attempted to characterize the mechanism underlying α‐melanocyte‐stimulating hormone (MSH)‐induced lipolysis, and compared it with that of the adrenocorticotro
Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes
✍ Scribed by Ying Gao; Danny Gauvreau; Katherine Cianflone
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 624 KB
- Volume
- 109
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Several studies have demonstrated increases in acylation stimulating protein (ASP), and precursor protein C3 in obesity, diabetes and dyslipidemia, however the nature of the regulation is unknown. To evaluate chronic hormonal and pharmaceutical mediated changes in ASP and potential mechanisms, 3T3‐L1 adipocytes were treated with physiological concentrations of relevant hormones and drugs currently used in treatment of metabolic diseases for 48 h. Medium ASP production and C3 secretion were evaluated in relation to changes in adipocyte lipid metabolism (cellular triglyceride (TG) mass, non‐esterified fatty acid (NEFA) release and real‐time FA uptake). Chylomicrons increased ASP production (up to 411 ± 133% P < 0.05), while leptin, triiodothyronine, and β‐blockers atenolol and propranolol had no effect. Dexamethasone, lovastatin, rosiglitazone and rimonabant decreased ASP production (−53 to −85%, P < 0.05), associated with a decrease in the precursor protein C3 (−37% to −65%, P < 0.01). By contrast, epinephrine, progesterone, testosterone, angiotensin II and metformin also decreased ASP (−54% to −100%, P < 0.05), but without change in precursor protein C3, suggesting a direct effect on convertase activity, possibly mediated by interference (except metformin) due to marked increases in NEFA (5.6–31‐fold, increased P < 0.05). Both lovastatin and metformin induced decreases in ASP were also associated with decreased TG mass (maximal −60%, P < 0.05) and real‐time FA uptake (maximum −75%, P < 0.05), suggesting a change in adipocyte differentiation status. These in vitro results are consistent with in vivo ASP profiles in subjects, and suggest that ASP may be regulated through precursor C3 availability, convertase activity and differentiation status. J. Cell. Biochem. 109: 896–905, 2010. © 2010 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Acylation stimulating protein (ASP) stimulates triglyceride synthesis and glucose transport via its receptor C5L2. In human studies, ASP is increased in insulin resistant states such as obesity, diabetes, polycystic ovary syndrome and late pregnancy (the latter two associated with alter
## Abstract Recent studies have shown the ability of apelin to restore glucose tolerance in obese and insulin‐resistant mice. Eicosapentaenoic acid (EPA) is a polyunsaturated fatty acid (PUFA) from the omega‐3 family that has many beneficial effects in obesity‐linked disorders. The aim of this stud
## Abstract Tunicamycin, an antibiotic that inhibits protein glycosylation, elicited a rapid depletion of insulin binding activity at the surface of 3T3‐L1 adipocytes. Disappearance of insulin receptors occurred more rapidly in the presence of tunicamycin than when protein synthesis was inhibited b
It is well established that somatotropin (GH) antagonizes insulin action in vivo and that supraphysiologic concentrations of GH frequently result in insulin resistance and glucose intolerance. However, the demonstration of an anti-insulin activity by GH in vitro has been difficult. This study, there
Differentiation of 3T3-LI adipocytes, monitored by accumulation of neutral lipid and by increase in a-glycerophosphate dehydrogenase activity, is accelerated by incubation of confluent 3T3-LI fibroblasts in media containing insulin, dexamethasone and isobutylmethylxantine (IBMX). IBMX inhibits cycli